Amgen to buy Horizon Therapeutics in $26.4B deal

By TOM MURPHY
AP Health Writer

Amgen will acquire Horizon Therapeutics, a biopharmaceutical company that focuses on treatments for rare, autoimmune diseases, for about $26.4 billion.  Each Horizon shareholder will receive $116.50 per share for each share they own. Amgen said Monday that the deal has an enterprise value of about $28.3 billion. U.S.-traded shares of Horizon soared about 30%, past $100, after the company confirmed late last month that it had begun “highly preliminary discussions” about an acquisition with Amgen, the French drugmaker Sanofi, and Johnson & Johnson’s Janssen division.